Akari Therapeutics announced the appointment of Beth-Anne Lang, as Senior Vice President, Regulatory Affairs. Ms. Lang has more than 20 years of experience in regulatory strategy, regulatory affairs, and drug development. She will start at Akari in this role on September 1, 2023. Before joining Akari, Ms. Lang was Senior Vice President, Regulatory Affairs and Pharmacovigilance for Enzyvant Therapeutics.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AKTX:
- Akari Therapeutics announces the European Commission granted ODD to nomacopan
- Akari Therapeutics appoints DiCicco as interim CFO
- Akari Therapeutics Appoints Experienced Life Sciences Executive Wendy DiCicco as Interim Chief Financial Officer
- Akari Therapeutics provides updates on development of nomacopan for HSCT-TMA
- Akari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan for Treatment of Geographic Atrophy